Heart failure (HF) is the fastest-growing cardiovascular condition worldwide. The immune system may play a role in the development of HF since this condition is associated with elevated pro-inflammatory cytokine levels. HF is a life-threatening disease, and there is an increasing demand for diagnostic biomarkers, prognostic factors, and therapeutic agents that can help treat it. Galectin-1 (Gal-1) is the prototype galectin of the lectin family. Multiple signal transduction pathways are regulated by Ras proteins, which act as a molecular switch in cells. Gal-1 regulates T and B cell activation, differentiation, and survival. Gal-1 has been linked to inflammation. Activated T cells produce Gal-1 through an autocrine apoptotic mechanism involving MEK1/ERK and p38 MAPK. In the cardiovascular system, atherosclerosis is facilitated by Gal-1. Heart disease, myocardial infarction, hypertension, and stroke can be caused by atherosclerotic plaque. HF and heart hypertrophy are caused by decreased cardiac L-type Ca2+ channel activity. Deregulation of Gal-1 and CaV1.2 in pathological cardiac hypertrophy suggests a possible target for anti-hypertrophic therapy. Rat hypertrophic cardiomyocytes express Gal-1 and CaV1.2 channels simultaneously. It has been reported that diastolic dysfunction (DD) is associated with elevated Gal-1 levels. The high Gal-1 level in subjects led to the lowest cumulative survival as a composite endpoint. Incidences of HF, DD, and serum Gal-1 levels correlated significantly. The ejection fraction was negatively correlated with Gal-1 and CRP concentrations. Based on two different approaches in mice and humans, Gal-1 was identified as a potential mediator of HF.
Background and Objective Bariatric surgery is one of methods for treatment of morbid obesity. Psychological factors can affect its outcome. This study aims to investigate the relationship between coping strategies and the outcome of bariatric surgery in patients with morbid obesity. Materials & Methods This prospective observational study was conducted ...
27 March 2021 in International Clinical Neuroscience Journal
Background: Parkinson’s disease is a chronic and progressive disease in which patients show symptoms of psychiatric diseases such as anxiety and depression leading to decreased quality of life. So far, few studies have been done in this field in Iran.Methods: The study is a cross-sectional study that investigates the prevalence of anxiety and depression and their related factors in patients with Parkinson’s disease. In this study, 74 patients with Parkinson’s disease and 74 healthy individuals were evaluated and using by Beck’s Depression and Anxiety Inventories.Results: The prevalence of depression and anxiety in patients with Parkinson’s was 37.83% and 78.38%, respectively. The mean score of depression and anxiety was significantly higher in the patient group (P<0.001). Older age, female sex, a higher level of education and a longer duration of illness were significantly associated with more depression and anxiety (P<0.05). Multiple regression models showed that age was a predictive factor in depression. With respect to anxiety, age and duration of the disease were predictive factors.Conclusion: The severity of depression and anxiety were significantly higher in patients with Parkinson’s disease compared to healthy individuals. Age and duration of the disease play a significant role in predicting the severity of depression and anxiety in such patients.
Background: Acute heart failure (AHF) is a significant cardiovascular syndrome characterized by either new-onset heart failure (HF) or acutely decompensated heart failure (ADHF), typically presenting with systemic and pulmonary congestion. The European Society of Cardiology has reinforced the importance of early guideline-directed medical therapy (GDMT) initiation and individualized decongestive strategies. This article explores current knowledge of AHF pathophysiology. The simplified hemodynamic paradigm previously used to explain AHF has been replaced over the past few decades by a more complex network of interacting mechanisms. Main text: The clinical presentation of AHF reflects a heterogeneous combination of cardiac abnormalities and systemic pathophysiological processes rather than a single disease entity. Despite overlapping clinical presentations, AHF arises from diverse underlying conditions and pathophysiological mechanisms. Left ventricular systolic or diastolic dysfunction elevates filling pressures, contributing to increased preload and afterload, which in turn promotes pulmonary congestion. End-organ dysfunction may result from the combined effects of venous congestion, impaired perfusion, and neurohormonal and inflammatory activation. Despite advances, limited progress in acute management may contribute to persistently poor outcomes in AHF patients. Conclusion: Initial management of AHF commonly includes intravenous diuretics for patients with congestion, while vasodilators and other therapies are selected according to congestion status, perfusion, blood pressure, hemodynamic profile, clinical phenotype, and the predominant underlying pathophysiological mechanism. This review examines pathophysiological processes contributing to AHF onset and progression, highlighting clinical implications and therapeutic targets.
18 January 2024 in SN Comprehensive Clinical Medicine
Background and Objective: Mental health is one of the essential dimensions of the human health. The World Health Organization (WHO) disability assessment schedule II (WHODAS II) has been introduced as an appropriate tool for mental health assessment. This study was conducted to prepare the Persian version of WHODAS II and ...